메뉴 건너뛰기




Volumn 14, Issue 1, 2015, Pages

Association of elevated apoA-I glycation and reduced HDL-associated paraoxonase1, 3 activity, and their interaction with angiographic severity of coronary artery disease in patients with type 2 diabetes mellitus

Author keywords

ApoA I glycation; Coronary artery disease; Diabetes mellitus; Paraoxonase

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; PARAOXONASE 3; UNCLASSIFIED DRUG; APOA1 PROTEIN, HUMAN; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; PON1 PROTEIN, HUMAN; PON3 PROTEIN, HUMAN;

EID: 84929312878     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-015-0221-4     Document Type: Article
Times cited : (45)

References (35)
  • 1
    • 79953192995 scopus 로고    scopus 로고
    • HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms
    • Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8:222-32.
    • (2011) Nat Rev Cardiol , vol.8 , pp. 222-232
    • Navab, M.1    Reddy, S.T.2    Lenten, B.J.3    Fogelman, A.M.4
  • 2
    • 84893353712 scopus 로고    scopus 로고
    • Cardioprotective functions of HDLs
    • Rye KA, Barter PJ. Cardioprotective functions of HDLs. J Lipid Res. 2014;55:168-79.
    • (2014) J Lipid Res , vol.55 , pp. 168-179
    • Rye, K.A.1    Barter, P.J.2
  • 3
    • 77953852336 scopus 로고    scopus 로고
    • Anti-oxidant properties of high-density lipoprotein and atherosclerosis
    • Podrez EA. Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin Exp Pharmacol Physiol. 2010;37:719-25.
    • (2010) Clin Exp Pharmacol Physiol , vol.37 , pp. 719-725
    • Podrez, E.A.1
  • 4
    • 57349114776 scopus 로고    scopus 로고
    • HDL: bridging past and present with a look at the future
    • Scanu AM, Edelstein C. HDL: bridging past and present with a look at the future. FASEB J. 2008;22:4044-54.
    • (2008) FASEB J , vol.22 , pp. 4044-4054
    • Scanu, A.M.1    Edelstein, C.2
  • 5
    • 34249305527 scopus 로고    scopus 로고
    • Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice
    • Ng CJ, Bourguard N, Hama SY, Shih D, Grijalva VR, Navab M, et al. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:1368-74.
    • (2007) Arterioscler Thromb Vasc Biol , vol.27 , pp. 1368-1374
    • Ng, C.J.1    Bourguard, N.2    Hama, S.Y.3    Shih, D.4    Grijalva, V.R.5    Navab, M.6
  • 6
    • 66349083560 scopus 로고    scopus 로고
    • Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to anti-oxidative function
    • Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ, Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to anti-oxidative function. Arterioscler Thromb Vasc Biol. 2009;29:870-6.
    • (2009) Arterioscler Thromb Vasc Biol , vol.29 , pp. 870-876
    • Davidson, W.S.1    Silva, R.A.2    Chantepie, S.3    Lagor, W.R.4    Chapman, M.J.5    Kontush, A.6
  • 7
    • 77954215428 scopus 로고    scopus 로고
    • The contribution of high density lipoprotein apolipoproteins and derivatives to serum paraoxonase-1 activity and function
    • James RW, Deakin SP. The contribution of high density lipoprotein apolipoproteins and derivatives to serum paraoxonase-1 activity and function. Adv Exp Med Biol. 2010;660:173-81.
    • (2010) Adv Exp Med Biol , vol.660 , pp. 173-181
    • James, R.W.1    Deakin, S.P.2
  • 9
    • 26844431924 scopus 로고    scopus 로고
    • Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation
    • Moore RE, Navab M, Millar JS, Zimetti F, Hama S, Rothblat GH, et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res. 2005;97:763-71.
    • (2005) Circ Res , vol.97 , pp. 763-771
    • Moore, R.E.1    Navab, M.2    Millar, J.S.3    Zimetti, F.4    Hama, S.5    Rothblat, G.H.6
  • 10
    • 79251573524 scopus 로고    scopus 로고
    • 4F peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice
    • Wool GD, Cabana VG, Lukens J, Shaw PX, Binder CJ, Witztum JL, et al. 4F peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice. FASEB J. 2011;25:290-300.
    • (2011) FASEB J , vol.25 , pp. 290-300
    • Wool, G.D.1    Cabana, V.G.2    Lukens, J.3    Shaw, P.X.4    Binder, C.J.5    Witztum, J.L.6
  • 11
    • 84886502812 scopus 로고    scopus 로고
    • Therapeutic approaches to the regulation of metabolism of high-density lipoprotein. Novel HDL-directed pharmacological intervention and exercise
    • Zhang B, Kawachi E, Miura S, Uehara Y, Matsunaga A, Kuroki M, et al. Therapeutic approaches to the regulation of metabolism of high-density lipoprotein. Novel HDL-directed pharmacological intervention and exercise. Circ J. 2013;77:2651-63.
    • (2013) Circ J , vol.77 , pp. 2651-2663
    • Zhang, B.1    Kawachi, E.2    Miura, S.3    Uehara, Y.4    Matsunaga, A.5    Kuroki, M.6
  • 12
    • 84882336972 scopus 로고    scopus 로고
    • Diabetes and vascular disease: pathophysiology, clinical consequences, and medical theraphy: part I
    • Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical theraphy: part I. Eur Heart J. 2013;34:2436-43.
    • (2013) Eur Heart J , vol.34 , pp. 2436-2443
    • Paneni, F.1    Beckman, J.A.2    Creager, M.A.3    Cosentino, F.4
  • 13
    • 84906846586 scopus 로고    scopus 로고
    • Serum levels of retinol-binding protein-4 are associated with the presence and severity of coronary artery disease
    • Lambadiari V, Kadoglou NP, Stasinos V, Maratou E, Antoniadis A, Kolokathis F, et al. Serum levels of retinol-binding protein-4 are associated with the presence and severity of coronary artery disease. Cardiovasc Diabetol. 2014;13:121.
    • (2014) Cardiovasc Diabetol , vol.13 , pp. 121
    • Lambadiari, V.1    Kadoglou, N.P.2    Stasinos, V.3    Maratou, E.4    Antoniadis, A.5    Kolokathis, F.6
  • 14
    • 84896699214 scopus 로고    scopus 로고
    • The relationship between serum hypoxia-inducible factor 1α and coronary artery calcification in asymptomatic type 2 diabetic patients
    • Li G, Lu WH, Ai R, Yang JH, Chen F, Tang ZZ. The relationship between serum hypoxia-inducible factor 1α and coronary artery calcification in asymptomatic type 2 diabetic patients. Cardiovasc Diabetol. 2014;13:52.
    • (2014) Cardiovasc Diabetol , vol.13 , pp. 52
    • Li, G.1    Lu, W.H.2    Ai, R.3    Yang, J.H.4    Chen, F.5    Tang, Z.Z.6
  • 15
    • 70349525016 scopus 로고    scopus 로고
    • Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes
    • Lu L, Pu LJ, Zhang Q, Wang LJ, Kang S, Zhang RY, et al. Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis. 2009;206:540-5. 20.
    • (2009) Atherosclerosis , vol.206 , pp. 540-545
    • Lu, L.1    Pu, L.J.2    Zhang, Q.3    Wang, L.J.4    Kang, S.5    Zhang, R.Y.6
  • 16
    • 84871899931 scopus 로고    scopus 로고
    • Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study
    • Fukushima Y, Daida H, Morimoto T, Kasai T, Miyauchi K, Yamagishi S, et al. Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study. Cardiovasc Diabetol. 2013;12:5.
    • (2013) Cardiovasc Diabetol , vol.12 , pp. 5
    • Fukushima, Y.1    Daida, H.2    Morimoto, T.3    Kasai, T.4    Miyauchi, K.5    Yamagishi, S.6
  • 17
    • 84887360982 scopus 로고    scopus 로고
    • Association of increased serum glycated albumin levels with low coronary collateralization in type 2 diabetic patients with stable angina and chronic total occlusion
    • Shen Y, Lu L, Ding FH, Sun Z, Zhang RY, Zhang Q, et al. Association of increased serum glycated albumin levels with low coronary collateralization in type 2 diabetic patients with stable angina and chronic total occlusion. Cardiovasc Diabetol. 2013;12:165.
    • (2013) Cardiovasc Diabetol , vol.12 , pp. 165
    • Shen, Y.1    Lu, L.2    Ding, F.H.3    Sun, Z.4    Zhang, R.Y.5    Zhang, Q.6
  • 19
    • 84876783625 scopus 로고    scopus 로고
    • Glycation of apoprotein A-I is associated with coronary artery plaque progression in type 2 diabetic patients
    • Pu LJ, Lu L, Zhang RY, Du R, Shen Y, Zhang Q, et al. Glycation of apoprotein A-I is associated with coronary artery plaque progression in type 2 diabetic patients. Diabetes Care. 2013;36:1312-20.
    • (2013) Diabetes Care , vol.36 , pp. 1312-1320
    • Pu, L.J.1    Lu, L.2    Zhang, R.Y.3    Du, R.4    Shen, Y.5    Zhang, Q.6
  • 20
    • 43049144209 scopus 로고    scopus 로고
    • Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and non-enzymatic glycation of apolipoprotein A-I
    • Nobecourt E, Zeng J, Davies MJ, Brown BE, Yadav S, Barter PJ, et al. Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and non-enzymatic glycation of apolipoprotein A-I. Diabetologia. 2008;51:1008-17.
    • (2008) Diabetologia , vol.51 , pp. 1008-1017
    • Nobecourt, E.1    Zeng, J.2    Davies, M.J.3    Brown, B.E.4    Yadav, S.5    Barter, P.J.6
  • 21
    • 34249082855 scopus 로고    scopus 로고
    • Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent
    • Lebherz C, Sanmiguel J, Wilson JM, Rader DJ. Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. CardiovascDiabetol. 2007;6:15.
    • (2007) CardiovascDiabetol , vol.6 , pp. 15
    • Lebherz, C.1    Sanmiguel, J.2    Wilson, J.M.3    Rader, D.J.4
  • 22
    • 58149153296 scopus 로고    scopus 로고
    • Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque
    • Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, Mukhamedova N, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res. 2008;103:1084-91.
    • (2008) Circ Res , vol.103 , pp. 1084-1091
    • Shaw, J.A.1    Bobik, A.2    Murphy, A.3    Kanellakis, P.4    Blombery, P.5    Mukhamedova, N.6
  • 23
    • 84855185039 scopus 로고    scopus 로고
    • Standards of medical care in diabetes-2012
    • American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35 Suppl 1:S11-63.
    • (2012) Diabetes Care , vol.35 , pp. S11-63
  • 24
    • 0347423198 scopus 로고    scopus 로고
    • Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
    • Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, IZZO JL, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-52.
    • (2003) Hypertension , vol.42 , pp. 1206-1252
    • Chobanian, A.V.1    Bakris, G.L.2    Black, H.R.3    Cushman, W.C.4    Green, L.A.5    IZZO, J.L.6
  • 25
    • 3142729178 scopus 로고    scopus 로고
    • Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    • Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.
    • (2004) Circulation , vol.110 , pp. 227-239
    • Grundy, S.M.1    Cleeman, J.I.2    Merz, C.N.3    Brewer, H.B.4    Clark, L.T.5    Hunninghake, D.B.6
  • 26
    • 0030975078 scopus 로고    scopus 로고
    • A comparison of quantitative computerized and human panel coronary endpoint measures: Implications for the design of angiographic trials
    • Mark WJ, Azen SP, Dunn M, Hodis HN. A comparison of quantitative computerized and human panel coronary endpoint measures: Implications for the design of angiographic trials. Control Clin Trials. 1997;18:168-79.
    • (1997) Control Clin Trials , vol.18 , pp. 168-179
    • Mark, W.J.1    Azen, S.P.2    Dunn, M.3    Hodis, H.N.4
  • 27
    • 0346962893 scopus 로고    scopus 로고
    • Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity
    • Solymoss BC, Bourassa MG, Campeau L, Sniderman A, Marcil M, Lesperance J, et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol. 2004;93:159-64.
    • (2004) Am J Cardiol. , vol.93 , pp. 159-164
    • Solymoss, B.C.1    Bourassa, M.G.2    Campeau, L.3    Sniderman, A.4    Marcil, M.5    Lesperance, J.6
  • 28
    • 0034120965 scopus 로고    scopus 로고
    • Impact of antioxidants and HDL on glycated LDL-induced generation of fibrinolytic regulators from vascular endothelial cells
    • Ren S, Shen GX. Impact of antioxidants and HDL on glycated LDL-induced generation of fibrinolytic regulators from vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20:1688-93.
    • (2000) Arterioscler Thromb Vasc Biol , vol.20 , pp. 1688-1693
    • Ren, S.1    Shen, G.X.2
  • 29
    • 58149384801 scopus 로고    scopus 로고
    • Paraoxonases (PON1, PON2, PON3) analysis in vitro and in vivo in relation to cardiovascular diseases
    • Aviram M, Rosenblat M. Paraoxonases (PON1, PON2, PON3) analysis in vitro and in vivo in relation to cardiovascular diseases. Methods MolBiol. 2008;477:259-76.
    • (2008) Methods MolBiol , vol.477 , pp. 259-276
    • Aviram, M.1    Rosenblat, M.2
  • 30
    • 78650913177 scopus 로고    scopus 로고
    • Novel N-terminal mutation of human apolipoprotein A-I reduces self-association and impairs LCAT activation
    • Weers PM, Patel AB, Wan LC, Guigard E, Kay CM, Hafiane A, et al. Novel N-terminal mutation of human apolipoprotein A-I reduces self-association and impairs LCAT activation. J Lipid Res. 2011;52(1):35-44.
    • (2011) J Lipid Res , vol.52 , Issue.1 , pp. 35-44
    • Weers, P.M.1    Patel, A.B.2    Wan, L.C.3    Guigard, E.4    Kay, C.M.5    Hafiane, A.6
  • 31
    • 79960699072 scopus 로고    scopus 로고
    • Modified apolipoprotein (apo) A-I by artificial sweetener causes severe premature cellular senescence and atherosclerosis with impairment of functional and structural properties of apoA-I in lipid-free and lipid-bound state
    • Jang W, Jeoung NH, Cho KH. Modified apolipoprotein (apo) A-I by artificial sweetener causes severe premature cellular senescence and atherosclerosis with impairment of functional and structural properties of apoA-I in lipid-free and lipid-bound state. Mol Cells. 2011;31:461-70.
    • (2011) Mol Cells , vol.31 , pp. 461-470
    • Jang, W.1    Jeoung, N.H.2    Cho, K.H.3
  • 32
    • 84857491459 scopus 로고    scopus 로고
    • Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions
    • 6375-86.35
    • Shao B, Pennathur S, Heinecke JW. Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. J Biol Chem. 2012;287(9):6375-86.35.
    • (2012) J Biol Chem , vol.287 , Issue.9
    • Shao, B.1    Pennathur, S.2    Heinecke, J.W.3
  • 33
    • 84871018411 scopus 로고    scopus 로고
    • Reduction of paraoxonase-1 activity may contribute the qualitative impairment of HDL particles in patients with type 2 diabetes
    • Murakami H, Tanabe J, Tamasawa N, Matsumura K, Yamashita M, Murakami H, et al. Reduction of paraoxonase-1 activity may contribute the qualitative impairment of HDL particles in patients with type 2 diabetes. Diabetes Res Clin Pract. 2013;99:30-8.
    • (2013) Diabetes Res Clin Pract , vol.99 , pp. 30-38
    • Murakami, H.1    Tanabe, J.2    Tamasawa, N.3    Matsumura, K.4    Yamashita, M.5    Murakami, H.6
  • 34
    • 84930377712 scopus 로고    scopus 로고
    • Is paraoxonase 1 a marker of cardiovascular risk in youth with type 1 diabetes
    • (Study about 109 cases) Presse Med. 2015 Mar 10. doi:. [Epub ahead of print]
    • Fekih O, Triki S, Hellara J, Neffati F, Chouchane S, Neji Gueddiche M, Fadhel Naijar M. Is paraoxonase 1 a marker of cardiovascular risk in youth with type 1 diabetes? (Study about 109 cases) Presse Med. 2015 Mar 10. doi:10.1016/j.lpm.2014.10.020. [Epub ahead of print]
    • Fekih, O.1    Triki, S.2    Hellara, J.3    Neffati, F.4    Chouchane, S.5    Neji Gueddiche, M.6    Fadhel Naijar, M.7
  • 35
    • 84929353965 scopus 로고    scopus 로고
    • Q192R polymorphism of paraoxonase 1 gene associated with insulin resistance in Mexican children
    • Alegria-Torres JA, Garcia-Dominquez ML, Cruz M, Aradillas-Garcia C. Q192R polymorphism of paraoxonase 1 gene associated with insulin resistance in Mexican children. Arch Med Res. 2015;46:78-83.
    • (2015) Arch Med Res , vol.46 , pp. 78-83
    • Alegria-Torres, J.A.1    Garcia-Dominquez, M.L.2    Cruz, M.3    Aradillas-Garcia, C.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.